【摘要】 目的探讨放射性核素89锶(89Sr)对晚期前列腺癌骨转移疼痛的治疗价值。方法回顾性分析67例因骨转移导致骨痛的晚期前列腺癌患者资料,按去势后病情和治疗分为3组:A组11例,切除睾丸后口服抗雄激素药物;B组27例,切除睾丸后口服抗雄激素药物加用89Sr治疗;C组29例,诊断为雄激素非依赖性前列腺癌,用89Sr治疗。采用视觉模拟疼痛评分(VAS)和Karnofsky生活质量评分对3组患者治疗前与治疗后4周的疼痛程度与生活质量进行比较分析。观察治疗后不良反应。结果治疗后4周,3组患者的骨痛明显改善,治疗前后VAS评分分别为:A组7.2、2.5,B组7.5、2.3,C组8.14、.7,P<0.05;生活质量明显提高,治疗前后Karnofsky评分分别为:A组50、75,B组50、80,C组45、65,P<0.05。2例患者发生不可逆性骨髓抑制,死于DIC。结论 89Sr治疗是缓解晚期前列腺癌骨痛的有效手段。更多还原

【Abstract】 Objective To investigate the role of Strontium-89 in the treatment of advanced prostatic cancer patients complaining of bone pain due to metastasis.Methods The clinical data of 67 cases of prostatic cancer with skeletal complications were retrospectively analyzed.Based on the post-castrating conditions and therapeutic approaches.the 67 cases were divided into 3 groups.11 cases in Group A received oral androgen blockade following orchectomy;27 cases in Group A received oral androgen blockade plus bonefos,a type of Strontium-89,following orchectomy;29 cases in Group C who had hormone-refractory prostatic cancer receives oral bonefos.The severity of bone pain and quality of life before treatment and 4 weeks after treatment were compared among the 3 groups using visual analogue score(VAS) and Karnofsky score of quality of life.The general adverse reactions and hematologic toxicity after treatment were observed.Results Compared with the state of pre-treatment,the patients got bone pain relief after 4 weeks’ treatment(VAS:7.2 vs 2.5 in Group A;7.5 vs 2.3 in Group B;8.1 vs 4.7 in Group C,respectively,P<0.05).and their quality of life improved significantly(Karnofsky score :50 vs 75 in Group A;50 vs 80 in Group B;45 vs 65 in Group C,P<0.05).The side effects were mild;two cases of patients occured irreversible myelosuppression and died DIC.Conclusion Strontium-89 are promising weapons for the management of advanced prostatic cancer related bone pain.更多还原